Durable complete response (CR) in a MCC patient treated with 15 mg/kg solnerstotug + cemiplimab. Patient continues on ...

A man and woman in Chattanooga both face several charges including aggravated child abuse after authorities found 4 kids ...

TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Jeremy Feffer - Managing Director, LifeSci Advisors Mary Szela - President & Chief Executive ...

UNC was a mistake. Not an egregious one, as the action on the court Tuesday conveyed. But that doesn't do much for West ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in ...

Now that the legislative session in Pierre is over, Governor Larry Rhoden is ready to travel around the state. Monday morning ...

Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in MayInitial Results From First Two ...

Luigi Mangione violated the "special treatment" he was afforded for his last court appearance when handwritten notes were ...

By incorporating healthspan science into clinical practice, some doctors are navigating a gray area between mainstream ...

The latest offering is the OptiMOS TDM24545S quad power module. It's a small, high-frequency (up to 2 MHz) DC-DC converter optimized for operation between 500 kHz and 1.5 MHz. The module includes ...

Actinium Pharmaceuticals, Inc.  (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...